glp-1 receptor agonists blindness risk Zepbound Lawsuit [2026 Update] GLP-1 Receptor Agonists and the
Description
(2018) 236:R2942
Both analyses were performed using the same methods as the primary analysis (ESM Tables 68)
UPDRS-III / CDR-SB, clinical rating scales
![glp-1 receptor agonists blindness risk Zepbound Lawsuit [2026 Update] GLP-1 Receptor Agonists and the](https://www.gastrojournal.org/cms/asset/2ee98cc6-58e7-4cf1-a0b6-4bad1c97ec39/ga1.jpg)
Hanrahan JP, de Boer IH, Bakris GL et al (2021) Effects of the soluble guanylate cyclase stimulator praliciguat in diabetic kidney disease: a randomized placebo-controlled clinical trial
Is GLP-1-related hair loss permanent
![glp-1 receptor agonists blindness risk Zepbound Lawsuit [2026 Update] GLP-1 Receptor Agonists and the](https://www.bmj.com/content/bmj/392/bmj-2025-086886/F1.medium.jpg)
These agents go beyond glycemic control
![glp-1 receptor agonists blindness risk Zepbound Lawsuit [2026 Update] GLP-1 Receptor Agonists and the](https://www.aoa.org/AOA/Images/News_2025/WIF_GLP1_1600x800_v1.png)